Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Alterity Therapeutics (ATHE) Other Non Operating Income (2015 - 2025)

Alterity Therapeutics' quarterly Other Non Operating Income came in at $12282.6 in Q4 2025, up 107.28% year-on-year from $5925.6 in Q4 2024, and up 107.28% quarter-over-quarter from -$168754.2 in Q4 2024.

Alterity Therapeutics has reported Other Non Operating Income for 10 years, with the latest figure at $12282.6 in Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 107.28% year-over-year to $12282.6; the trailing twelve-month figure through Dec 2025 stood at -$449955.0 (up 66.67% YoY), and the FY2025 full-year result was -$42980.1, down 124.97% from the prior year.
  • Other Non Operating Income for Q4 2025 stood at $12282.6, up from -$168754.2 in the prior quarter.
  • The five-year high for Other Non Operating Income was $12282.6 in Q4 2025, with the low at -$887856.6 in Q4 2021.
  • Average Other Non Operating Income over 5 years is -$267562.3, with a median of -$168754.2 recorded in 2024.
  • Year-over-year, Other Non Operating Income tumbled 7673.09% in 2024 and jumped 107.28% in 2025.
  • Tracing ATHE's Other Non Operating Income over 5 years: stood at -$887856.6 in 2021, then surged by 66.69% to -$295711.7 in 2022, then soared by 100.75% to $2228.3 in 2023, then plunged by 7673.09% to -$168754.2 in 2024, then surged by 107.28% to $12282.6 in 2025.
  • The last three Other Non Operating Income figures came in at $12282.6 (Q4 2025), -$168754.2 (Q4 2024), and $2228.3 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 12,282.56
Dec 31, 2024 -168,754.15
Dec 31, 2023 2,228.34
Dec 31, 2022 -295,711.72
Dec 31, 2021 -887,856.63
Dec 31, 2019 87,328.62
Dec 31, 2018 142,967.80
Dec 31, 2017 -469,835.65
Dec 31, 2016 -372,092.82
Dec 31, 2015 1.90 Mn